BRIXADI is the first and only long-acting buprenorphine injectable with both weekly and monthly doses. Patients currently on a transmucosal buprenorphine-containing product can be switched to an ...
Credit: Braeburn. Brixadi (weekly) and Brixadi (monthly) are different formulations. Brixadi ® (buprenorphine) extended-release subcutaneous injection is now available for the treatment of moderate to ...
BRIXADI is now available for healthcare settings and pharmacies through a restricted distribution program called the BRIXADI REMS and is administered only by a healthcare professional. PLYMOUTH ...
Brixadi (buprenorphine) is a brand-name injection that’s prescribed for opioid use disorder. As with other drugs, Brixadi can cause side effects, such as injection site reactions and respiratory ...
LUND, Sweden, June 1, 2020 /PRNewswire/ -- Camurus AB (NASDAQ: CAMX) (STO: CAMX) today announces that the company's US partner Braeburn has submitted a request for final approval of Brixadi™ ...
Brixadi (buprenorphine) is a prescription drug used to treat opioid use disorder in adults. Brixadi can cause side effects that range from mild to serious. Examples include headache, constipation, and ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results